Benzinga | Nov 9, 2021 11:44AM EST

Immutep Reports Improved And Statistically Significant Survival Benefit For Three Key Patient Groups In Final Phase IIb AIPAC Study Results In Metastatic Breast Cancer

* Final Overall Survival (OS) data supports Phase III clinical development of efti in combination with paclitaxel in metastatic breast cancer

* OS benefit trend in total population, with median survival benefit of +2.9 months from efti plus chemotherapy, compared to chemotherapy plus placebo

* Statistically significant and clinically meaningful OS benefit confirmed now in three predefined patient subgroups (patients < 65 years, low monocytes and luminal B) with improved data versus data presented in December 2020

* Survival benefit of +7.5 months, +19.6 months and +4.2 months in the < 65 years, low monocytes and luminal B subgroups, respectively. Reflects a benefit of > 50%, > 150% and > 33%, respectively.

* Efti increased circulating CD8 T cells which is significantly correlated with improved OS

* Investor webcast Wednessday, 17 November 2020, at 8.00 am Australian Eastern Daylight Time (AEDT), details below.